Treace Medical Concepts, INC Form 4 insider transactions

A Treace Medical Concepts executive, Scot Michael Elder, sold 4,544 shares of common stock to cover tax obligations related to vesting restricted stock units.

Aaron Berutti, SVP of Sales at Treace Medical Concepts, disposed of 4,821 shares of common stock to cover tax obligations related to restricted stock units.

Treace Medical Concepts CEO John T. Treace reported the disposal of 11,905 shares for tax purposes and disclosed his beneficial ownership of over 5 million shares through various direct and indirect holdings.

Guy Guglielmino, Chief Commercial Officer of Treace Medical Concepts, was granted 363,000 restricted stock units (RSUs) on December 1, 2024.

A Treace Medical Concepts executive acquired 15,550 shares of common stock through performance stock unit vesting and disposed of 3,787 shares to cover tax obligations.

Scot Michael Elder, Chief Legal & Compliance Officer and Corporate Secretary of Treace Medical Concepts, Inc., acquired 200,000 shares of common stock on September 30, 2024.

CEO John T. Treace of Treace Medical Concepts, Inc. recently purchased 50,000 shares of common stock at an average price of $5.3126 per share.

Sean F. Scanlan, Chief Innovation Officer at Treace Medical Concepts, Inc., exercised stock options and acquired common stock on September 12, 2024.

Director James Treace purchased 84,000 shares of Treace Medical Concepts at an average price of $5.9647 on August 15, 2024.

CEO John T. Treace of Treace Medical Concepts, Inc. recently purchased 85,000 shares of common stock at an average price of $6.0037 per share.

Aaron Berutti, SVP of Sales at Treace Medical Concepts, reports the acquisition of 60,450 restricted stock units (RSUs) on August 9, 2024.

Mark Hair, CFO of Treace Medical Concepts, reports the acquisition of 207,260 restricted stock units (RSUs) on August 9, 2024.

Sean F. Scanlan, Chief Innovation Officer at Treace Medical Concepts, Inc., reports acquisition of 120,900 shares of common stock through restricted stock units.

Scot Michael Elder, Chief Legal & Compliance Officer and Corporate Secretary of Treace Medical Concepts, Inc., reports the acquisition of restricted stock units.

CEO John T. Treace of Treace Medical Concepts, Inc. (TMCI) recently purchased 45,000 shares of common stock at an average price of $5.88.

Director James Treace of Treace Medical Concepts, Inc. (TMCI) purchased 25,000 shares of common stock at a weighted average price of $6.0531 on May 31, 2024.

Director James Treace acquired 25,000 shares of Treace Medical Concepts at an average price of $5.2025 on May 29, 2024, increasing his direct holdings.

Director James T. Treace of Treace Medical Concepts, Inc. (TMCI) purchased 50,000 shares of common stock at an average price of $5.0695 on May 28, 2024.

Director Richard Mott of Treace Medical Concepts, Inc. recently purchased 18,000 shares of TMCI stock at an average price of $5.1945 per share.

Richard Mott, a director at Treace Medical Concepts, Inc., purchased 12,100 shares of common stock at an average price of $4.9938 on May 22, 2024.

Director Richard W. Mott reports acquisition of restricted stock units and stock options in Treace Medical Concepts, Inc.

Director Jane E. Kiernan reports acquisition of stock options and restricted stock units in Treace Medical Concepts, Inc.

Director Deepti Jain reports acquisition of shares and options in Treace Medical Concepts, Inc.

Director John K. Bakewell acquired shares and options in Treace Medical Concepts, Inc. through restricted stock units and a stock option grant.

Director Lance A. Berry reports acquisition of restricted stock units and stock options in Treace Medical Concepts, Inc.

Director Betsy Hanna acquired shares and stock options in Treace Medical Concepts, Inc. on May 21, 2024, including restricted stock units and stock options that vest over time.

Director Lawrence W. Hamilton acquired stock options and restricted stock units in Treace Medical Concepts, Inc.

CEO John T. Treace of Treace Medical Concepts, Inc. (TMCI) recently purchased 100,000 shares of common stock at an average price of $5.5617 per share.

Director Jane E. Kiernan purchased 19,356 shares of Treace Medical Concepts (TMCI) at an average price of $5.1664 on May 14, 2024.

Treace Medical Concepts CEO John T. Treace purchased 150,000 shares of common stock at a weighted average price of $5.1187 on May 14, 2024.